众生药业(002317) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥675,794,415.22, representing a year-on-year increase of 9.73% compared to ¥615,880,806.76 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2022 was ¥74,590,425.78, a 31.41% increase from ¥56,762,950.08 in Q1 2021[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥126,167,446.23, up 12.49% from ¥112,162,463.85 in the previous year[3]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.09, an increase of 28.57% from ¥0.07 in Q1 2021[3]. - The total operating revenue for the first quarter was CNY 675,794,415.22, an increase of 9.6% compared to CNY 615,880,806.76 in the same period last year[33]. - The net profit for the current period is approximately ¥73.61 million, compared to ¥54.85 million in the previous period, indicating an increase of about 34%[39]. - The total comprehensive income for the current period is approximately ¥78.82 million, compared to ¥61.66 million in the previous period, reflecting an increase of about 27.7%[39]. Cash Flow and Assets - The net cash flow from operating activities decreased by 48.86% to ¥25,671,106.19 from ¥50,198,713.06 in the same quarter last year[3]. - The company's cash and cash equivalents at the end of the period amounted to CNY 1,152,024,850.15, up from CNY 1,016,367,813.78 at the beginning of the year, reflecting a growth of 13.4%[26]. - The total assets at the end of Q1 2022 were ¥5,198,506,320.86, reflecting a 6.05% increase from ¥4,901,980,877.51 at the end of the previous year[3]. - The total liabilities increased to CNY 1,544,384,070.06 from CNY 1,363,840,852.63, marking an increase of 13.2%[32]. - The company's inventory at the end of the period was CNY 462,399,578.22, slightly up from CNY 452,198,760.24, showing an increase of 2.5%[26]. - The net cash flow from investing activities was -$115,090,246.22, an improvement from -$149,879,682.70 in the prior period[46]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 69,567[13]. - Zhang Yuchong and Zhang Yuli each hold 11.37% of shares, totaling 92,640,500 shares[13]. - The company has not identified any related party relationships among the top 10 shareholders[16]. - The total number of shares held by shareholder Lü Liangfeng is 11,868,194, including shares held through margin trading accounts[16]. Incentive Plans - The company approved a restricted stock incentive plan to grant 5.84 million shares at a price of 5.58 RMB per share[17]. - The restricted stock plan has a lock-up period of 12, 24, and 36 months, with specific release ratios of 40%, 30%, and 30%[17]. - The employee stock ownership plan is set to not exceed 5.7 million shares, representing 0.70% of the total share capital[21]. - The stock repurchase price for the employee stock ownership plan is also set at 5.58 RMB per share[21]. - The company completed the registration of the restricted stock incentive plan on March 22, 2022[18]. - The total number of shares granted in the adjusted incentive plan is 5.78 million shares[18]. Operational Strategies - The company has actively adapted to changes in the pharmaceutical industry and optimized its operational strategies, leading to sustained revenue growth[8]. - The company plans to expand its market presence and continue developing new products and technologies[24]. Borrowings and Financial Changes - The company experienced a 90.69% increase in short-term borrowings, rising to ¥362,307,690.00 from ¥190,000,000.00 in the previous year[10]. - The company's short-term borrowings rose significantly to CNY 362,307,690.00 from CNY 190,000,000.00, an increase of 90.6%[29]. - The company recorded a financial expense of approximately ¥13.72 million, compared to a financial income of approximately -¥0.31 million in the previous period[36]. - Cash inflow from financing activities amounted to $312,147,065.79, a decrease of approximately 33.9% compared to $472,307,422.06 last year[46]. - Cash outflow for debt repayment was $80,000,000.00, significantly lower than $261,000,000.00 in the previous period, showing a reduction of about 69.4%[46]. Research and Development - Research and development expenses increased to approximately ¥26.38 million from ¥23.74 million, which is an increase of about 11%[36]. - The company received FDA approval for the clinical trial of its innovative drug ZSP1273, aimed at preventing and treating influenza[25]. Audit and Reporting - The company did not undergo an audit for the first quarter report[47]. - The report was issued by the board of directors of Guangdong Zhongsheng Pharmaceutical Co., Ltd. on April 24, 2022[48].